Show simple item record

dc.contributor.authorAmeratunga, M
dc.contributor.authorColeman, N
dc.contributor.authorWelsh, L
dc.contributor.authorSaran, F
dc.contributor.authorLopez, J
dc.date.accessioned2018-06-21T09:50:58Z
dc.date.issued2018-04-27
dc.identifier.citationOncotarget, 2018, 9 (32), pp. 22802 - 22816
dc.identifier.issn1949-2553
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1893
dc.identifier.eissn1949-2553
dc.identifier.doi10.18632/oncotarget.24896
dc.description.abstractImmunotherapeutics have revolutionized the management of solid malignancies over the last few years. Nevertheless, despite relative successes of checkpoint inhibitors in numerous solid tumour types, success in tumours of the central nervous system (CNS) has been lacking. There are several possible reasons for the relative lack of success of immunotherapeutics in this setting, including the immune microenvironment of glioblastoma, lymphocyte tracking through the blood-brain barrier (BBB) into the central nervous system and impairment of drug delivery into the CNS through the BBB. This review utilizes the cancer-immunity cycle as a conceptual framework through which the specific challenges associated with the development of immunotherapeutics for CNS malignancies can be viewed.
dc.formatElectronic-eCollection
dc.format.extent22802 - 22816
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleCNS cancer immunity cycle and strategies to target this for glioblastoma.
dc.typeJournal Article
dcterms.dateAccepted2018-03-11
rioxxterms.versionofrecord10.18632/oncotarget.24896
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-04-27
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOncotarget
pubs.issue32
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.publication-statusPublished
pubs.volume9
pubs.embargo.termsNot known
icr.researchteamMedicine (de Bono Prostate)en_US
dc.contributor.icrauthorLopez, Juanitaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0